Suvretta Capital Management LLC Invests $3.14 Million in United Therapeutics Corporation $UTHR

Suvretta Capital Management LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 7,500 shares of the biotechnology company’s stock, valued at approximately $3,144,000.

Several other large investors have also bought and sold shares of the company. WealthCollab LLC raised its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. lifted its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $536.12 on Friday. The firm has a 50 day simple moving average of $486.67 and a 200 day simple moving average of $460.13. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The company has a market cap of $23.50 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $6.19 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 338,947 shares of company stock worth $165,516,573 in the last quarter. Insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on UTHR shares. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Wells Fargo & Company boosted their target price on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Finally, UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $548.09.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.